References
- Jankowski J, Franklin J. Faculty Opinions recommendation of Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2020. doi:10.341 0/f.734004835.793572727
- Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015. pp. 567–610. doi:10.1089/thy.2014.0335
- Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol. 2000;22: 351–358.
- Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary Thyroid Carcinoma. Clinical Oncology. 2010. pp. 475–485. doi:10.1016/j.clon.2010.05.002
- Elisei R, Bottici V, Cappagli V, Ramone T, Tacito A, Ciampi R, et al. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Annales d’Endocrinologie. 2019. pp. 187–190. doi:10.1016/j.ando.2019.04.014
- Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH. Medullary thyroid carcinoma. Cancer. 2000. pp. 1139–1148. doi:10.1002/(sici)1097-0142(20000301)88:5<;1139::aid-cncr26>3.0.co;2-z
- Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2007;141: 90–95.
- Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92: 4725–4729.
- Das T, Cagan R. Drosophila as a novel therapeutic discovery tool for thyroid cancer. Thyroid. 2010;20: 689–695.
- Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86: 5658–5671.
- Jindrichová S, Vcelák J, Vlcek P, Neradilová M, Nemec J, Bendlová B. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol. 2004;183: 257–265.
- Hodak SP, Burman KD. The Calcitonin Conundrum—Is It Time for Routine Measurement of Serum Calcitonin in Patients with Thyroid Nodules? The Journal of Clinical Endocrinology & Metabolism. 2004. pp. 511–514. doi:10.1210/jc.2003-031983
- Mazzaferri EL. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. Yearbook of Endocrinology. 2007. pp. 238–243. doi:10.1016/s0084-3741(08)70120-3
- Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997;103: 60–69.
- Mezei T, Kolcsár M, Pașcanu I, Vielh P. False positive cases in thyroid cytopathology – the experience of a single laboratory and a systematic review. Cytopathology. 2021. doi:10.1111/cyt.12984
- Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2: 1023–1029.
- Zhao L, Ma B. Radiomics Features of Different Sizes of Medullary Thyroid Carcinoma (MTC) and Papillary Thyroid Carcinoma (PTC) Tumors: A Comparative Study. Clin Med Insights Oncol. 2022;16: 11795549221097675.
- Liu M-J, Liu Z-F, Hou Y-Y, Men Y-M, Zhang Y-X, Gao L-Y, et al. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Oncotarget. 2017;8: 27520–27528.
- Lei R, Wang Z, Qian L. Ultrasonic Characteristics of Medullary Thyroid Carcinoma: Differential From Papillary Thyroid Carcinoma and Benign Thyroid Nodule. Ultrasound Q. 2021 [cited 2 Jun 2021]. doi:10.1097/RUQ.0000000000000508
- Rossi ED, Adeniran AJ, Faquin WC. Pitfalls in Thyroid Cytopathology. Surg Pathol Clin. 2019;12: 865–881.
- Szántó Z, Kun IZ, Jung J. Pajzsmirigyrák társulása autoimmun thyreoiditiszekkel. Orvostudományi Értesítő (Buletin of Medical Sciences). 2008;81: 103–107.
- Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol . 2015;82: 280–285.
- Malheiros DC, Canberk S, Poller DN, Schmitt F. Thyroid FNAC: Causes of false-positive results. Cytopathology. 2018;29: 407–417.
- Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the Cytologic and Molecular Features of Medullary Thyroid Carcinoma. Advances In Anatomic Pathology. 2014. pp. 31–40. doi:10.1097/pap.0000000000000004
- Chand G, Lal H, Mayilvaganan S, Jaiswal S, Prasad R, Siddiqui F, et al. Cytomorphological features of medullary thyroid carcinoma: An analysis based on 41 ultrasoundguided fine-needle aspiration specimens. World j endocr surg. 2018;10: 108–118.
- Liu C-Y, Chen C-C, Bychkov A, Agarwal S, Zhu Y, Hang J-F, et al. Constitutive Cytomorphologic Features of Medullary Thyroid Carcinoma Using Different Staining Methods. Diagnostics (Basel). 2021;11. doi:10.3390/diagnostics11081396
- Trimboli P, Giannelli J, Marques B, Piccardo A, Crescenzi A, Deandrea M. Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis. Endocrine. 2021;75: 33–39.
- Costante G, Meringolo D. Calcitonin as a biomarker of C cell disease: recent achievements and current challenges. Endocrine. 2020. pp. 273–280. doi:10.1007/s12020-019-02183-6
- Vierhapper H, Niederle B, Bieglmayer C, Kaserer K, Baumgartner-Parzer S. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid. 2005;15: 1267–1272.
- Gambardella C, Offi C, Patrone R, Clarizia G, Mauriello C, Tartaglia E, et al. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma? BMC Endocr Disord. 2019;19: 45.
- Samà MT, Rossetto Giaccherino R, Gallo M, Felicetti F, Maletta F, Bonelli N, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma. J Cancer Res Clin Oncol. 2016;142: 2023–2029.
- Kim SJ, Yun HJ, Shin S-J, Lee YS, Chang H-S. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center. Frontiers in Endocrinology. 2021. doi:10.3389/fendo.2021.747704
- Machens A, Lorenz K, Dralle H. Prediction of biochemical cure in patients with medullary thyroid cancer. British Journal of Surgery. 2020. pp. 695–704. doi:10.1002/bjs.11444
- Kovacs CS, Ralston SH. Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporosis International. 2015. pp. 2223–2241. doi:10.1007/s00198-015-3149-3
- Verbeek HH, de Groot JWB, Sluiter WJ, Muller Kobold AC, van den Heuvel ER, Plukker JT, et al. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane Database Syst Rev. 2020;3: CD010159.
- Niederle MB, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? Thyroid. 2020;30: 974–984.
- Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid. 2011;21: 1199–1207.
- Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goellner JR, Grant CS, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67: 934–940.
- Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77: 1556–1565.
- Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol . 1998;48: 265–273.
- Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276: 1575–1579.
- Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020 Jul 28;67(7):669-717.